224 related articles for article (PubMed ID: 21649688)
1. New therapeutic options for metastatic malignant insulinomas.
de Herder WW; van Schaik E; Kwekkeboom D; Feelders RA
Clin Endocrinol (Oxf); 2011 Sep; 75(3):277-84. PubMed ID: 21649688
[TBL] [Abstract][Full Text] [Related]
2. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
[TBL] [Abstract][Full Text] [Related]
3. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
[TBL] [Abstract][Full Text] [Related]
4. Multidisciplinary management of refractory insulinomas.
Brown E; Watkin D; Evans J; Yip V; Cuthbertson DJ
Clin Endocrinol (Oxf); 2018 May; 88(5):615-624. PubMed ID: 29205458
[TBL] [Abstract][Full Text] [Related]
5. Systemic therapy for advanced pancreatic neuroendocrine tumors.
Kulke MH
Semin Oncol; 2013 Feb; 40(1):75-83. PubMed ID: 23391115
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia.
Bernard V; Lombard-Bohas C; Taquet MC; Caroli-Bosc FX; Ruszniewski P; Niccoli P; Guimbaud R; Chougnet CN; Goichot B; Rohmer V; Borson-Chazot F; Baudin E;
Eur J Endocrinol; 2013 May; 168(5):665-74. PubMed ID: 23392213
[TBL] [Abstract][Full Text] [Related]
7. [Drug therapy for neuroendocrine tumours].
Tóth M
Orv Hetil; 2013 Sep; 154(39):1556-64. PubMed ID: 24058101
[TBL] [Abstract][Full Text] [Related]
8. Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma.
Ong GS; Henley DE; Hurley D; Turner JH; Claringbold PG; Fegan PG
Eur J Endocrinol; 2010 May; 162(5):1001-8. PubMed ID: 20164213
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of metastatic malignant insulinomas. 2 cases].
Mounedji-Boudiaf L; Rougier P; Culine S; de Baere T; Lasser P; Escudier B; Ducreux M; Kaloustian E; Droz JP; Roche A
Presse Med; 1995 May; 24(19):894-6. PubMed ID: 7638129
[TBL] [Abstract][Full Text] [Related]
10. [Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan].
Ito T; Igarashi H; Jensen RT; Takayanagi R
Fukuoka Igaku Zasshi; 2012 Jul; 103(7):131-7. PubMed ID: 22978065
[No Abstract] [Full Text] [Related]
11. Targeted agents in treatment of neuroendocrine tumors of pancreas.
Karampelas IN; Syrigos KN; Saif MW
JOP; 2014 Jul; 15(4):351-3. PubMed ID: 25076341
[TBL] [Abstract][Full Text] [Related]
12. Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors.
Liakakos T; Roukos DH
Future Oncol; 2011 Sep; 7(9):1025-9. PubMed ID: 21919689
[No Abstract] [Full Text] [Related]
13. New target therapies for patients with neuroendocrine tumors of the pancreas.
Baltogiannis G; Katsios C; Roukos DH
Expert Rev Gastroenterol Hepatol; 2011 Oct; 5(5):563-6. PubMed ID: 21910571
[No Abstract] [Full Text] [Related]
14. Perspectives in the development of novel treatment approaches.
Yao JC; Catena L; Colao A; Paganelli G
Tumori; 2010; 96(5):858-73. PubMed ID: 21302643
[No Abstract] [Full Text] [Related]
15. Everolimus dramatically improves glycemic control in unresectable metastatic insulinoma: a case report.
Asayama M; Yamada-Murano T; Hara H; Ooki A; Kurosumi M; Yamaguchi K
Jpn J Clin Oncol; 2014 Feb; 44(2):186-90. PubMed ID: 24367043
[TBL] [Abstract][Full Text] [Related]
16. Treatment: symptomatic treatment of hypoglycaemia.
Tabarin A; Goichot B;
Ann Endocrinol (Paris); 2013 Jul; 74(3):196-9. PubMed ID: 23791453
[No Abstract] [Full Text] [Related]
17. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.
Naraev BG; Strosberg JR; Halfdanarson TR
Oncology; 2012; 83(3):117-27. PubMed ID: 22797357
[TBL] [Abstract][Full Text] [Related]
18. Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2.
Romeo S; Milione M; Gatti A; Fallarino M; Corleto V; Morano S; Baroni MG
Horm Res; 2006; 65(3):120-5. PubMed ID: 16479142
[TBL] [Abstract][Full Text] [Related]
19. [Erlotinib, sunitinib, and everolimus].
Takahashi M
Nihon Rinsho; 2015 Mar; 73 Suppl 3():409-13. PubMed ID: 25857058
[No Abstract] [Full Text] [Related]
20. Advances in pancreatic neuroendocrine tumor treatment.
van der Veldt AA; Kleijn SA
N Engl J Med; 2011 May; 364(19):1873; author reply 1873-5. PubMed ID: 21561355
[No Abstract] [Full Text] [Related]
[Next] [New Search]
